Generated: May 25, 2017
|Title:||Sulphated glycosaminoglycuronan with antithrombotic activity|
|Abstract:||The present invention relates to sulphated glycosamino glycuronan with antithrombotic activity consisting essentially of salts of dermatan sulphate, chondroitin sulphate and heparan sulphate, characterized by a) an average molecular weight between 4000 and 8000 daltons; b) a nitrogen content between 2.4 and 3.0%; c) a sulphur content between 7.5 and 9.5%; d) a sodium content between 9 and 11%; e) a dermatan sulphate content between 5 and 25%; f) a chondroitin sulphate content less than 9%; g) an anti-Xa activity between 11 and 20 .mu./mg; and h) an antithrombin III dependent antithrombin activity of less than 1 .mu./mg.|
|Inventor(s):||Van Dedem; Gijsbert W. K. (Oss, NL), Van Hou Denhoven; Francois E. A. (Heesch, NL), Meuleman; Dirk G. (Oss, NL), Moelker; Huibert C. T. (Megen, NL), Sanders; Adrianus L. M. (Uden, NL)|
|Assignee:||Akzo N.V. (Arnhem, NL)|
1. Sulphated glycosaminoglycuronan having antithrombotic activity, which is essentially free of heparin, comprising salts of dermatan sulphate in an amount of from 5% to 25% by weight,
chondroitin sulphate in an amount of from 0% to 9% by weight and heparan sulphate in an amount of from 66% to 95% by weight, wherein the sulphated glycosaminoglycuron has
a) an average molecular weight between 4000 and 8000 daltons;
b) a nitrogen content between 2.4 and 3.0%;
c) a sulphur content between 7.5 and 9.5%;
d) a sodium content between 9 and 11%;
e) an anti-Xa activity between 11 and 20 units/mg; and
f) an antithrombin III dependent antithrombin activity of less than 1 unit/mg.
2. Process for the manufacture of sulphated glycosaminoglycuronan that is essentially free of heparin, comprising breaking down mammalian tissue by enzyme lysis, contacting the product of enzyme lysis with an anion exchanger to bind sulphated glycosaminoglycuronan containing active material, and eluting said active material from the anion exchanger with aqueous salt solution, whereby preliminary separation from heparin is effected, thereafter diafiltering the eluate against an aqueous salt solution using an apparatus with a nominal cutoff of no greater than 10,000 daltons, binding the diafilter product to an anion exchanger, eluting with an aqueous salt solution and precipitating with an organic solvent that is miscible with water.
3. Process according to claim 2, wherein porcine intestinal mucosa is digested by proteolytic enzymes, the aqueous salt solutions are solutions of sodium chloride, the diafiltration is performed in an apparatus with a nominal cutoff of a relative molecular mass of about 5500 daltons, and the precipitation is performed with gradually increasing amounts of methanol in water.
4. Pharmaceutical composition comprising pharmaceutically acceptable auxiliaries and an effective amount of sulphated glycosaminoglycuronan according to claim 1 to provide antithrombotic activity.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.